Consensus Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/01/2026 GMT			5-day change	1st Jan Change
17.28 ^USD	-3.57%		-6.24%	-16.12%

11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
11-13	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Evolution of the Average Target: Neurogene Inc.

Evolution of the Target Price: Neurogene Inc.

Changes in Analyst Recommendations: Neurogene Inc.

1f90b7e9.514Lhjnc2F4rSGiLcTJuzITpcB303sX_adgjzTkju1k.jhBi3lOouQh7GQHsAVxZgduZF1e5qqPJWbAbnH577D2AK0m_XJTvKxgeAw~e3248ae36ca43679034f22594eb9c3a1

Analysts' recommendations: Neurogene Inc.

11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
09/10/25	Neurogene Plans to Initiate Dosing in Registrational Trial in Q4 2025	MT
16/05/25	Neurogene Shares Drop After Downgrade From Baird	MT
16/05/25	Baird Downgrades Neurogene to Neutral From Outperform, Adjusts Price Target to $24 From $38	MT
27/06/24	BMO Initiates Neurogene at Outperform With $65 Price Target	MT
11/06/24	Baird Initiates Neurogene With Outperform Rating, $54 Price Target	MT
29/04/24	Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	MT
21/03/24	William Blair Initiates Neurogene With Outperform Rating	MT
08/01/24	HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	MT
05/01/24	Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	MT
09/05/23	Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating	MT
03/01/23	Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy	MT
15/11/22	Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21	MT
15/11/22	Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	MT
12/09/22	BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3	MT
12/09/22	HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating	MT
10/08/22	Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating	MT
06/07/22	Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target	MT
31/05/22	Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating	MT
10/05/22	Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating	MT
02/03/22	Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating	MT
06/08/21	NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target	MT
06/01/21	NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NEUROGENE INC.					+229.24%
	LONZA GROUP AG					+22.32%
	IQVIA HOLDINGS INC.					+6.22%
	BEONE MEDICINES AG					+19.03%
	CELLTRION, INC.					+7.11%
	REVOLUTION MEDICINES, INC.					-25.03%
	MEDPACE HOLDINGS, INC.					-8.85%
	EUROFINS SCIENTIFIC SE					-4.24%
	ICON PUBLIC LIMITED COMPANY					+13.4%
	Average					+28.80%
	Weighted average by Cap.					+7.68%